Navigation Links
AstraZeneca And Cellworks Collaborate To Find New Treatment For Tuberculosis

LONDON, July 2, 2012 /PRNewswire/ -- AstraZeneca and Cellworks today announced a collaboration supported by the Wellcome Trust to speed the design of novel combination therapies for the treatment of drug-sensitive and resistant tuberculosis. This collaboration will also pave the way for the creation of platforms and approaches to handle Multi Drug Resistant Tuberculosis (MDR-TB), a condition that is reaching epidemic proportions in many developing parts of the world.

Current therapies for tuberculosis (TB) are based on creating combinations of three to four drugs and cycling through ad-hoc regimens, which are largely ineffective against MDR-TB. Together, Cellworks and AstraZeneca will pull from a pool of existing anti-infective drugs and attempt to find an effective combination with better efficacy and lower toxicity than the treatment regimens provided today.

The traditional process of designing an ideal drug combination is lengthy and expensive as there are several thousand possible combinations and the search space is too large to be handled by conventional wet-lab techniques. Under this collaboration, Cellworks will use its proprietary predictive platform, which it pioneered in oncology and autoimmune disorders, to model drug MDR-TB and  rationally identify 'synergistic combinations' that might have the highest efficacy and lowest possible toxic burden compared to all currently available combinations. AstraZeneca will then validate the top ten most effective combinations identified by Cellworks in-vitro in its laboratories, followed by validation using in-vivo models.

Dr. Anand Anandkumar, Managing Director, Cellworks Group India said: "Cellworks is honoured to take the lead on this unique drug development project which has the potential to save thousands of lives globally. Its results may also have positive implications in other infectious disease areas where drug resistance is prevalent. We are proud to be working with scientists from AstraZeneca on such a socially valuable project, funded by one of the world's leading science foundations."

Dr. Manos Perros, Head of the AstraZeneca Infection Innovative Medicines Unit, said: "AstraZeneca is pleased to join this effort to speed the delivery of improved treatment combinations for TB patients worldwide. Our continued investment in infectious disease research has positioned us to collaborate with organisations like Cellworks who share our passion for medical innovation. AstraZeneca would like to acknowledge and thank the Wellcome Trust for funding this important work. We believe that new medicines and new combination therapies to treat TB will be delivered through a concerted effort from multiple partners rather than one company's lab."

Dr. Richard Seabrook, Head of Business Development at the Wellcome Trust, said: "MDR-TB is both a major global healthcare threat and a scientific challenge. Tackling it requires new approaches to drug discovery and we are delighted to be supporting this collaboration which has a strong mix of both innovation and drug development expertise."

About Tuberculosis
Tuberculosis (TB) is caused by bacteria (Mycobacterium tuberculosis) that most often affect the lungs. TB is spread from person to person through the air. About one-third of the world's population has latent TB, which means people have been infected by TB bacteria but are not (yet) ill with disease and cannot transmit the disease.

TB occurs in every part of the world. Standard anti-TB drugs have been used for decades, and resistance to the medicines is growing. Disease strains that are resistant to a single anti-TB drug have been documented in every country surveyed.

About Cellworks Group, Inc.
Cellworks Group Inc. is a biopharmaceutical company designing and developing innovative, but derisked, therapeutic programs. The Cellworks therapeutics pipeline is based on an approach using proprietary validated technology platform which allows emulation of disease physiology computationally and prediction of clinical outcomes. The current disease focus area include Rheumatoid Arthritis, Epithelial based cancers and infectious diseases. For more information please visit:

About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:

About The Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust's breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests.

SOURCE AstraZeneca
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Zacks Bull and Bear of the Day Highlights: Discover Financial Services, POSCO, AstraZeneca, Bayer and Takeda Pharmaceutical
2. Optimer Pharmaceuticals and Specialised Therapeutics Australia Collaborate to Commercialize Fidaxomicin for Clostridium difficile Infection in Australia and New Zealand
3. JDRF and BD Collaborate to Develop More Accurate and Reliable Glucose Monitoring Devices for People with Type 1 Diabetes
4. BD and Heart to Heart International Collaborate on Second Volunteer Service Trip to Help Improve Healthcare in Haiti
5. The Rogosin Institute and Hebrew Home Collaborate to Provide New Dialysis Service for Residents and Patients
6. QIAGEN and Cardinal Health Collaborate to Offer Molecular Diagnostic Products to Smaller and Mid-sized U.S. Hospitals
7. Aethlon Medical (AEMD) Note: Cancer Treatment Publication Authored by Aethlon Medical Researchers Now Available
8. Elektas Gamma Knife and Radiation Therapy Systems for Cancer Treatment Take Top Three Places in 2012s Best in KLAS for Radiation Therapy
9. Researchers Evaluate Computer-based Treatment for People with Schizophrenia
10. Breast Cancer Detection and Treatment Recovers Slowly from Big Losses During Recession
11. U.K. Cancer Patient is Worlds First to Benefit from Treatment Combining Elektas New Beam-shaping Innovation and High-speed Arc Therapy
Post Your Comments:
(Date:12/1/2015)... 2015 ... of the "2016 Europe Enteric ... Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, ... offering. --> ) ... "2016 Europe Enteric Disease Testing ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... Dec. 1, 2015   Craneware, Inc ., ... solutions, today announced the company will showcase a ... ® solution at the American Society ... Meeting . The new features are focused on ... monitoring and managing enterprise-wide pharmacy charges to ensure ...
Breaking Medicine Technology:
(Date:12/1/2015)... FL (PRWEB) , ... December 01, 2015 , ... ... announces the Multi Jar, a container patent that allows for easier packing and organizing ... the US is worth $90 billion," says Scott Cooper, CEO and Creative Director of ...
(Date:12/1/2015)... ... ... Royal River Natural Foods — a locally-owned, independent natural health store in ... nutritional supplement creatine, along with resistance training for a year, had more new bone ... report is part of the December 2015 issue of Natural Insights for Well Being®, ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an article published ... discrimination claim against the U.S. Department of Health and Human Services, claiming that any ... plans are breaking the clause in the law prohibiting the denial of coverage for ...
(Date:12/1/2015)... ... December 01, 2015 , ... Califia Farms , one of ... iconic bottle has won top honors in Beverage World Magazine’s Global Packaging Design Awards, ... that it has been selected as a 2015 U.S.A. Taste Champion in the American ...
(Date:12/1/2015)... ... ... Growth in medical payments per workers’ compensation claim in Louisiana slowed from ... care, according to a recent study by the Workers Compensation Research Institute (WCRI). ... payments per claim with more than seven days of lost time continued to be ...
Breaking Medicine News(10 mins):